Sanofi abandons eczema drug approval efforts in another blow to OX40 class

RegulatoryrejectedNegative

AI Analysis

Summary

Sanofi has abandoned approval efforts for an eczema drug targeting the OX40 pathway, representing a significant setback for the company and the OX40 drug class.

Outcome Details

Sanofi abandons approval efforts for OX40 class eczema drug

Importance:7/10

Sentiment:

-0.80

regulatory_setbackeczemaOX40approval_abandonment

Related Companies

$SNY

Read the original article

Published by yahoo_finance on July 24, 2026 2:20 PM

Read Original